We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.04 | -0.12% | 32.77 | 32.74 | 33.00 | 33.03 | 32.73 | 33.00 | 1,281,689 | 21:15:00 |
From May 2023 to May 2024
By Adria Calatayud
Roche Holding confirmed its 2023 guidance after a fall in sales for the first nine months, with growth in its pharmaceutical division overshadowed by a sharp drop in diagnostics sales due to weaker Covid-19-related demand.
The Swiss pharma giant said Thursday that sales for the first nine months of the year amounted to 44.05 billion Swiss francs ($49 billion), down 6% on year. Sales at the company's pharma division rose 1%, and diagnostics sales fell 25%.
At constant currency, Roche said sales grew 1% in the first nine months of the year and 7% in the third quarter alone.
The company said it continues to expect a decline in group sales for 2023 in the low single-digit range at constant-exchange rates, with core earnings per share forecast to perform broadly in line with the sales drop at constant-exchange rates.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
October 19, 2023 01:33 ET (05:33 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
